Kwang Dong Pharmaceutical Overview
- Year Founded
-
1963
- Status
-
Public
- Employees
-
1,049
- Stock Symbol
-
009290
- Investments
-
11
- Share Price
-
$4.70
- (As of Friday Closing)
Kwang Dong Pharmaceutical General Information
Description
Kwang Dong Pharmaceutical Co Ltd is a drug store company. It manufactures and markets medicines and health-aids foods. The company originally focuses on the oriental medicine based drugs but succeeds in health aid beverages. Kwang's products include Vitamins, Antipyretic, Analgesic, Eye drops and amongst others.
Contact Information
Website
www.ekdp.comCorporate Office
- Gasan Building, 85
- Seochojungang-ro, Seocho
- Seoul, 11220
- South Korea
Corporate Office
- Gasan Building, 85
- Seochojungang-ro, Seocho
- Seoul, 11220
- South Korea
Kwang Dong Pharmaceutical Stock Performance
As of 13-Nov-2026, Kwang Dong Pharmaceutical’s stock price is $4.70. Its current market cap is $234M with 49.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.70 | $4.74 | $3.33 - $8.84 | $234M | 49.7M | 161K | $0.35 |
Kwang Dong Pharmaceutical Financials Summary
As of 30-Jun-2026, Kwang Dong Pharmaceutical has a trailing 12-month revenue of $1.18B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 300,721 | 238,941 | 227,242 | 218,849 |
| Revenue | 1,176,422 | 1,166,095 | 1,202,488 | 1,158,327 |
| EBITDA | 41,546 | 39,549 | 56,279 | 49,205 |
| Net Income | 15,037 | 14,734 | 29,669 | 28,273 |
| Total Assets | 849,251 | 916,890 | 794,500 | 836,566 |
| Total Debt | 195,027 | 210,560 | 194,112 | 182,855 |
Kwang Dong Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kwang Dong Pharmaceutical Patents
Kwang Dong Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024242502-A1 | Enzymatic preparation method for 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol | Inactive | 25-May-2023 | ||
| WO-2023106777-A1 | Vital melon (kctc14699bp) and anti-obesity composition comprising extract thereof | Inactive | 10-Dec-2021 | ||
| JP-2015183003-A | Male sterility preventive and therapeutic pharmaceutical composition containing mixtures of rehmannia glutinosa liboschitz var.purpurae makino, lycium chinense miller, aquillaria agallocha roxburgh, poria cocos wolf, panax ginseng ca meyer and honey as active ingredients | Active | 25-Mar-2014 | ||
| WO-2014163260-A1 | Composition for skin whitening containing corn silk extract | Inactive | 02-Apr-2013 | ||
| JP-2014011971-A | Production method of corn hair tea | Active | 04-Jul-2012 |
Kwang Dong Pharmaceutical Signals
Kwang Dong Pharmaceutical Investments & Acquisitions (11)
Kwang Dong Pharmaceutical’s most recent deal was a Secondary Transaction - Private with Precision Biosensor for . The deal was made on 02-Oct-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Precision Biosensor | 02-Oct-2024 | Secondary Transaction - Private | Diagnostic Equipment | ||
| Issuing Electronic Securities (Finger / Kwangdong Pharmaceutical) | 24-Jul-2024 | Joint Venture | Other Financial Services | ||
| Kwangdong Healthbio | 02-Jan-2024 | Merger/Acquisition | Pharmaceuticals | ||
| CT Bio | 31-Jan-2023 | Corporate | Monitoring Equipment | ||
| Vitrosys | 01-Aug-2022 | Later Stage VC | Drug Discovery |
Kwang Dong Pharmaceutical ESG
Risk Overview
Risk Rating
Updated September, 30, 2025
43.95 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,999
Rank
Percentile
Pharmaceuticals
Industry
of 952
Rank
Percentile
Pharmaceuticals
Subindustry
of 438
Rank
Percentile
Kwang Dong Pharmaceutical Exits (4)
Kwang Dong Pharmaceutical’s most recent exit was on 31-Jan-2023 from CT Bio. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| CT Bio | 31-Jan-2023 | Completed |
|
||
| BM Stage | 29-Jun-2022 | Completed |
|
||
| QuadMedicine | 09-May-2022 | Completed |
|
||
| Adolor | 01-Nov-1997 | Later Stage VC | Completed |
Kwang Dong Pharmaceutical Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Korea ePlatform | Seoul, South Korea | 2000 | |
| KD Investment (Credit Finance) |
Kwang Dong Pharmaceutical FAQs
-
When was Kwang Dong Pharmaceutical founded?
Kwang Dong Pharmaceutical was founded in 1963.
-
Where is Kwang Dong Pharmaceutical headquartered?
Kwang Dong Pharmaceutical is headquartered in Seoul, South Korea.
-
What is the size of Kwang Dong Pharmaceutical?
Kwang Dong Pharmaceutical has 1,049 total employees.
-
What industry is Kwang Dong Pharmaceutical in?
Kwang Dong Pharmaceutical’s primary industry is Beverages.
-
Is Kwang Dong Pharmaceutical a private or public company?
Kwang Dong Pharmaceutical is a Public company.
-
What is Kwang Dong Pharmaceutical’s stock symbol?
The ticker symbol for Kwang Dong Pharmaceutical is 009290.
-
What is the current stock price of Kwang Dong Pharmaceutical?
As of 13-Nov-2026 the stock price of Kwang Dong Pharmaceutical is $4.70.
-
What is the current market cap of Kwang Dong Pharmaceutical?
The current market capitalization of Kwang Dong Pharmaceutical is $234M.
-
What is Kwang Dong Pharmaceutical’s current revenue?
The trailing twelve month revenue for Kwang Dong Pharmaceutical is $1.18B.
-
What is Kwang Dong Pharmaceutical’s annual earnings per share (EPS)?
Kwang Dong Pharmaceutical’s EPS for 12 months was $0.35.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process